Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s CSPC Pharmaceutical Group Ltd (HKG: 1093). The agreement, formalized through a memorandum of understanding (MoU) between their respective subsidiaries, Pharmaniaga LifeScience Sdn Bhd and CSPC Ouyi Pharmaceutical Co., Ltd, encompasses research and development (R&D), manufacturing, and commercialization of innovative pharmaceutical and biopharmaceutical products.
Initial Focus on mRNA Vaccine Pipeline
The collaboration initially focuses on CSPC’s mRNA vaccine pipeline, which targets a range of diseases including flu, respiratory syncytial virus, zoster, HPV, and dengue. Pharmaniaga plans to commercialize these vaccines in Malaysia and other relevant territories, expanding access to these critical health interventions. The two firms will also assess the market prospects for CSPC’s other innovative products and pipeline candidates, indicating a strategic approach to expanding their product offerings.
Building on an Existing Relationship
This deal marks an expansion of the existing relationship between Pharmaniaga and CSPC. Pharmaniaga already manufactures azithromyicin dihydrate API for CSPC, demonstrating a foundation of trust and collaboration. The new agreement signifies a deepening partnership aimed at leveraging each company’s strengths to enhance their presence in the global pharmaceutical market.-Fineline Info & Tech
